MOLECULAR EXPRESS, INC — Department of Health and Human Services SBIR Phase I: NIAID
MOLECULAR EXPRESS, INC — SBIR Phase I award from Department of Health and Human Services.
Phase I SBIR feasibility signal
- Phase I awards fund proof-of-concept work. For capture teams, they mark early interest from Department of Health and Human Services in a technical approach.
- Watch for Phase II follow-ons from the same firm/topic family — that conversion path is where budgets and transition pressure rise.
- Obligated amount $298,479. Cross-check similar awards in the same agency and technology tags for going-rate context.
- Topic code NIAID links this award to a solicitation family — search the same topic stem for incumbents and recompete timing.
- Amount
- $298,479
- Agency
- Department of Health and Human Services · National Institutes of Health
- Program / Phase
- SBIR · Phase I
- Topic
- NIAID
- Solicitation
- PA20-260
- NAICS
- —
- Place of performance
- CA
- Period
- 2022-07-08 → 2023-06-30
Description
Project SummaryThe principal goal of this project is to demonstrate that the FDA-approved anthelminthic drug, niclosamide, can be reformulated in a synthetic lung surfactant which can be aerosolized for the treatment of infections caused by respiratory viruses. The studies proposed in this SBIR Phase I application will be focused on testing this concept by suspending niclosamide loaded liposomes in our proprietary lung surfactant technology (Niclosurf) and testing candidate Niclosurf formulations in a mouse influenza challenge model. The effectiveness of Niclosurf as a treatment for respiratory viral infections caused by influenza will be evaluated.